It was demonstrated that soy isoflavone intake was associated with a reduction in prostate cancer diagnosis in men with a clinically confirmed risk of prostate cancer (risk ratio = 0.49, 95% CI = 0.26–0.95), but no significant results were demonstrated regarding the relationship between the intake of soy isoflavones and the serum PSA level in men with confirmed prostate disease. Here, PROS1 is linked to prostate cancer.